Primary Evaluation To Safety And Value Of China-made Tirofiban In Patients With Acute Coronary Syndrome Undergoing PCI

Objective To investigate the values and safety in especial dose of china-made Tirofiban in patients with acute coronary syndrome(ACS) undergoing percutaneous coronary intervention(PCI). Methods One hundred twenty-seven patients suffered from acute coronary syndromes between January 2006 and June 2007 were selected and divided into two groups according to dose(full dose and semis).These patients who had treated with heparins(including low molecular weight heparins), clopidogrel sulfate and aspirin were observed on clinical characteristics,PCI outcomes, The composite end point events consisted of the major cardiovascular events(MASE) during the hospital days. Results The clinical characteristics were similar for two group(P>0.05).PCI outcomes showed that three artery stenosis was 40.26% in full dose group, 44% in semis group; two coronary artery stenosis was 37.66% in full dose group, 30% in semis group; single artery stenosis was 22.08% in full dose group, 26% in semis group, no statistical significant difference observed. the incidence proportion of MACE during hospitalization, non-fatal myocardial infarction, the full dose group was 3.90% (3 cases), 4.00% in semis group (2 cases); Death in full dose group was 1.30% (1 case), 2.00% in semis group (1 case). The total rate of MACE was 33.77% in full dose group (26 case), 34.00% in semis group (17 case). There was no statistical significant diffeence between the two groups. Conclusion The results suggest that Tirofiban is a safe and tolerable therapy drug for ACS patients to PCI,To have the dose halved will not increase incidence rate of heart-blood vessel event.